MediWound Ltd. (MDWD)
NASDAQ: MDWD · Real-Time Price · USD
17.99
-0.04 (-0.22%)
Apr 25, 2025, 4:00 PM EDT - Market closed
MediWound Revenue
In the year 2024, MediWound had annual revenue of $20.22M with 8.22% growth. MediWound had revenue of $5.84M in the quarter ending December 31, 2024, with 9.40% growth.
Revenue (ttm)
$20.22M
Revenue Growth
+8.22%
P/S Ratio
8.90
Revenue / Employee
$182,180
Employees
111
Market Cap
195.40M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 20.22M | 1.54M | 8.22% |
| Dec 31, 2023 | 18.69M | -7.81M | -29.48% |
| Dec 31, 2022 | 26.50M | 2.73M | 11.50% |
| Dec 31, 2021 | 23.76M | 2.00M | 9.19% |
| Dec 31, 2020 | 21.76M | -10.03M | -31.54% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 410.06B |
| Johnson & Johnson | 89.33B |
| Merck & Co. | 63.92B |
| AbbVie | 57.37B |
| AstraZeneca | 54.07B |
| Novartis AG | 51.72B |
| Eli Lilly and Company | 45.04B |
| Thermo Fisher Scientific | 42.90B |
MDWD News
- 5 weeks ago - MediWound Ltd. (MDWD) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 5 weeks ago - MediWound Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update - GlobeNewsWire
- 7 weeks ago - MediWound to Report Fourth Quarter and Full Year 2024 Financial Results - GlobeNewsWire
- 2 months ago - MediWound Announces Phase III CIDS Publication on NexoBrid® for Pediatric Burn Care - GlobeNewsWire
- 2 months ago - MediWound to Present at the 45th Annual TD Cowen Health Care Conference - GlobeNewsWire
- 2 months ago - MediWound to launch Phase III trial for venous leg ulcers - Reuters
- 2 months ago - MediWound Initiates the VALUE Global Phase III Pivotal Trial of EscharEx® for Treatment of Venous Leg Ulcers - GlobeNewsWire
- 5 months ago - MediWound Ltd. (MDWD) Q3 2024 Earnings Call Transcript - Seeking Alpha